Search

Displaying results 8271 - 8280 of 9704 in total
  1. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  2. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. … LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    AVI-4557

    go.drugbank.com/drugs/DB05447
    Experimental

    AVI-4557 is therefore indicated to limit toxicity for patients receiving highly-toxic therapeutic drugs for treatment of anxiety, cancer, and a number of other serious conditions. … AVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently

  4. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. … FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-cholesterol and total cholesterol in a broad range of animal species.

  5. Drug

    PH-284

    go.drugbank.com/drugs/DB05452
    Experimental

    PH-284 belongs to a new family of new chemical entities called vomeropherins. … Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages.

  6. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes.

  7. Drug

    Pozanicline

    go.drugbank.com/drugs/DB05458
    Investigational

    ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity

  8. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, an...

  9. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. … Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration.

  10. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential.